Pulmonx Corporation: Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal System

Pulmonx Corporation (Nasdaq: LUNG) announced the publication of CONVERT Trial results for its AeriSeal System, showing 75.8% of patients with severe emphysema and collateral ventilation had successful treatment. The study suggests the system could enable subsequent treatment with Zephyr Valves, improving lung function and quality of life. Pulmonx is now conducting the CONVERT II Pivotal Trial to support a U.S. FDA Premarket Approval application for the AeriSeal System.

Original reporting
Published Nov 17, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$LUNG
Bullish
medium confidence
Mentioned
$LUNG
Relevance
7/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$LUNGBullishMed
01

Why it matters

The publication provides concrete clinical performance for converting CV+ to CV- and reports subsequent valve outcomes, strengthening the scientific rationale for the ongoing CONVERT II pivotal IDE trial aimed at US FDA PMA support.

02

Market read

Traders may reassess the probability of regulatory success and commercial expansion for AeriSeal-enabled Zephyr Valve treatment based on newly published conversion and follow-on valve outcome data.

03

What to watch

US PMA timing and the operational execution of CONVERT II enrollment and follow-on valve outcomes may matter more than the published conversion endpoint alone.

Relevance 7/10Novelty 7/10Timing: today’s publication of CONVERT Trial results

Background

Pulmonx’s AeriSeal System is intended to close collateral ventilation channels so patients with severe emphysema can become eligible for Zephyr Endobronchial Valve treatment.

Company-level read

Ticker impact

$LUNGBullishMedium confidence
Context

Pulmonx published CONVERT Trial results showing AeriSeal converted collateral-ventilation positive lobes to collateral-ventilation negative in 75.8% of evaluable patients.

Expected impact

Likely positive bias as the market prices improved probability of expanding Zephyr Valve eligibility via AeriSeal conversion results.

Evidence & confidence

The article discloses specific conversion and follow-on valve outcome rates and reiterates CONVERT II enrollment intended to support a US PMA application, which are direct catalysts for the company’s regulatory and commercial narrative.

Market effects

Reinforces the COPD interventional device theme that patient selection and procedural sequencing can expand treatable populations.

Primarily US-listed biotech/device sentiment, with trial sites in Europe and Australia.

Supports a global regulatory and adoption narrative for bronchoscopic lung volume reduction technologies.

Counterpoint

Because CONVERT is open-label and single-arm, investors may discount the conversion rate until CONVERT II provides pivotal, regulator-grade evidence.

Key entities

  • Pulmonx Corporation

    Nasdaq-listed developer of minimally invasive COPD treatments, including Zephyr Endobronchial Valves and the AeriSeal System.

  • AeriSeal System

    Bronchoscopic system evaluated in CONVERT to convert collateral ventilation status from CV+ to CV-.

  • CONVERT Trial

    Prospective, open-label, multicenter, single-arm study (NCT04559464) evaluating AeriSeal conversion followed by Zephyr Valve treatment.

  • CONVERT II Pivotal Trial

    Multinational pivotal IDE study (NCT06035120) enrolling about 200 patients, targeting US FDA PMA support using six-month results.

Related articles

$LUNGMed

Pulmonx reports trial results for emphysema treatment system

Pulmonx (LUNG) reported CONVERT Trial results for its AeriSeal System in severe emphysema patients, showing 75.8% success in converting collateral ventilation status. Treated patients achieved 88.9% target lobe volume reduction at 45 days, with improvements in lung function and quality of life. The company is enrolling patients in the CONVERT II Pivotal Trial for U.S. FDA approval.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$LUNGHigh

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.